In accordance with the legislation of the Czech Republic, the Company provides services only to qualified investors!

Verve Therapeutics (VERV) Financial results for the second quarter of 2021.

12.08.2021

GAAP net loss is -$6.66, that is $3.25 worse than the same period last year.

Cash and cash equivalents are $417.6 million as of June 30, 2021.